FDA Approves Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent dMMR/MSI-H Endometrial Cancer
Recommended
FDA Approves Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent dMMR/MSI-H Endometrial Cancer
On July 31, 2023, The US Food and Drug Administration (FDA) approved dostarlimab-gxly plus carboplatin and paclitaxel for adult patients with advanced or recurrent endometrial cancer that is dMMR or MSI-H, as detected by an FDA-approved test.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->